Cover Image

Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh

Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient’s eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon’s fibroblast (HTF) lea...

Full description

Saved in:
Bibliographic Details
Main Author: Md Noh, Siti Munirah
Format: Book Section
Language:English
Published: Institute of Graduate Studies, UiTM 2018
Subjects:
RC Internal Medicine
RM Therapeutics. Pharmacology
Online Access:http://ir.uitm.edu.my/id/eprint/20553/1/ABS_SITI%20MUNIRAH%20MD%20NOH%20TDRA%20VOL%2013%20IGS%2018.pdf
http://ir.uitm.edu.my/id/eprint/20553/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.uitm.ir.20553
record_format eprints
spelling my.uitm.ir.205532018-07-06T05:58:56Z http://ir.uitm.edu.my/id/eprint/20553/ Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh Md Noh, Siti Munirah RC Internal Medicine RM Therapeutics. Pharmacology Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient’s eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon’s fibroblast (HTF) leads to significant cases of surgical failure. Anti-vascular endothelial growth factor (VEGF) has become the focus in current scar modulation strategy. Improved bleb morphology following trabeculectomy augmented with ranibizumab has been reported. However, mechanism of actions of ranibizumab on HTF is not well understood. Therefore, this in vitro study was conducted to elucidate mechanism of actions of ranibizumab on HTF. HTF used in this study were propagated from Tenon’s capsule obtained from patients undergoing trabeculectomy. Firstly, isolated and characterized HTF were treated with different concentrations of ranibizumab in serum and serum-free media for 24 and 48 hours and then HTF viability was measured using MTT assay. Then, HTF were extracted to measure the expression of collagen Type 1 (COL1A1), fibronectin (FN), transforming growth factor-β1 and -β2 (TGF-β1 &TGF-β2) using qRT-PCR and ELISA. The experiment was followed with metabolomics profiling which was performed to identify the most significant metabolite regulated by ranibizumab… Institute of Graduate Studies, UiTM 2018 Book Section PeerReviewed text en http://ir.uitm.edu.my/id/eprint/20553/1/ABS_SITI%20MUNIRAH%20MD%20NOH%20TDRA%20VOL%2013%20IGS%2018.pdf Md Noh, Siti Munirah (2018) Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh. In: The Doctoral Research Abstracts. IGS Biannual Publication, 18 (18). Institute of Graduate Studies, UiTM, Shah Alam.
institution Universiti Teknologi Mara
building Tun Abdul Razak Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Teknologi Mara
content_source UiTM Institutional Repository
url_provider http://ir.uitm.edu.my/
language English
topic RC Internal Medicine
RM Therapeutics. Pharmacology
spellingShingle RC Internal Medicine
RM Therapeutics. Pharmacology
Md Noh, Siti Munirah
Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
description Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient’s eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon’s fibroblast (HTF) leads to significant cases of surgical failure. Anti-vascular endothelial growth factor (VEGF) has become the focus in current scar modulation strategy. Improved bleb morphology following trabeculectomy augmented with ranibizumab has been reported. However, mechanism of actions of ranibizumab on HTF is not well understood. Therefore, this in vitro study was conducted to elucidate mechanism of actions of ranibizumab on HTF. HTF used in this study were propagated from Tenon’s capsule obtained from patients undergoing trabeculectomy. Firstly, isolated and characterized HTF were treated with different concentrations of ranibizumab in serum and serum-free media for 24 and 48 hours and then HTF viability was measured using MTT assay. Then, HTF were extracted to measure the expression of collagen Type 1 (COL1A1), fibronectin (FN), transforming growth factor-β1 and -β2 (TGF-β1 &TGF-β2) using qRT-PCR and ELISA. The experiment was followed with metabolomics profiling which was performed to identify the most significant metabolite regulated by ranibizumab…
format Book Section
author Md Noh, Siti Munirah
author_facet Md Noh, Siti Munirah
author_sort Md Noh, Siti Munirah
title Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_short Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_full Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_fullStr Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_full_unstemmed Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_sort mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / siti munirah md noh
publisher Institute of Graduate Studies, UiTM
publishDate 2018
url http://ir.uitm.edu.my/id/eprint/20553/1/ABS_SITI%20MUNIRAH%20MD%20NOH%20TDRA%20VOL%2013%20IGS%2018.pdf
http://ir.uitm.edu.my/id/eprint/20553/
_version_ 1685649356857802752
score 13.211869

Similar Items